Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: O...
Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study
About this item
Full title
Author / Creator
Publisher
Cheshire: Springer Healthcare
Journal title
Language
English
Formats
Publication information
Publisher
Cheshire: Springer Healthcare
Subjects
More information
Scope and Contents
Contents
Demographics, baseline, and clinical characteristics (SAS) Characteristics Total N = 399 Age, years, mean ± SD 42.9 ± 13.5 Female, n (%) 272 (68.2) BMI, kg/m2, mean ± SD 28.4 ± 6.8 [N = 373] Country, n (%) Belgium 33 (8.3) Canada 36 (9.0) Czech Republic 25 (6.3) France 20 (5.0) Germany 86 (21.6) Greece 106 (26.6) Italy 57 (14.3) Spain 17 (4.3) Unit...
Alternative Titles
Full title
Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_99b0aed743ab47f79d535ed54575f5a4
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_99b0aed743ab47f79d535ed54575f5a4
Other Identifiers
ISSN
2193-8210
E-ISSN
2190-9172
DOI
10.1007/s13555-024-01271-4
